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Abstract
Using genome-wide CRISPR screens to understand endocrine drug resistance, we discovered 
ARID1A and other SWI/SNF complex components as the most critical factors required for 
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response to two classes of Estrogen Receptor-alpha (ER) antagonists as these SWI/SNF-specific 
gene knockouts lead to drug resistance. Unexpectedly, ARID1A was also the top candidate for 
response to the BET inhibitor JQ1, but in the opposite direction, where loss of ARID1A sensitised 
breast cancer cells to BET inhibition. We show that ARID1A is a repressor which binds chromatin 
at ER cis-regulatory elements. However, ARID1A elicits repressive activity in an enhancer-
specific, but FOXA1-dependent and active ER-independent manner. Deletion of ARID1A resulted 
in loss of Histone Deacetylase 1 (HDAC1) binding, increased histone 4 lysine acetylation and 
subsequent BRD4-driven transcription and growth. ARID1A mutations are more frequent in 
treatment-resistant disease and our findings provide mechanistic insight into this process whilst 
revealing rational treatment strategies for these patients.
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Introduction
Three quarters of breast cancers are driven by Estrogen Receptor-alpha (ER) 1, which 
utilises a slew of associated proteins to access compacted chromatin (including Forkhead 
Box A1 (FOXA1) and GATA Binding Protein-3 (GATA3)) 2, 3. Drugs that target the ER 
pathway are effective treatments for a majority of women with ER+ disease 1, but a 
substantial fraction of women will present with de novo or acquired drug resistance. 
Mechanisms of resistance are varied and include changes in co-factor levels, growth factor 
activated transcription and mutations in ER and associated transcription factors and co-
factors 4.
Significant effect has been invested in identifying associated protein complexes that 
influence ER transcriptional activity 5–7. A role for the ATP-dependent chromatin 
remodeling complex SWItch mating type/Sucrose Non-Fermenting chromatin remodeling 
complex (SWI/SNF), has been linked with nuclear receptor function 8,9, where this complex 
modulates chromatin accessibility. There are three ATPase complexes, BAF, P-BAF and a 
recently identified non-canonical BAF (ncBAF) and the BRG1 and BRM subunits are 
common between the three complexes. However, there are proteins that are specific to BAF 
(ARID1A, ARID1B, DPF1/2/3, SS18), P-BAF complex (ARID2, Polybromo (PBRM1), 
BRD7) and ncBAF (BRD9, GLTSCR1, GLTSCR1L) 10,11. Previous work has shown a 
physical association between the SWI/SNF component BRG1 and ER and a requirement for 
BRG1 for ER-mediated transcriptional activity 12,13. The recruitment of SWI/SNF to the ER 
complex, is mediated by shared co-factors 14 and BRG1 occupancy at ER regulatory 
elements, coincides with increased localised histone acetylation 15. On a locus-specific level, 
BRG1 can bind to ER regulatory elements independent of ER 12, suggesting that the 
SWI/SNF complex might contribute to chromatin preparation prior to ER recruitment.
The SWI/SNF complex is important for chromatin regulation and gene expression 16, it is 
mutated in ~20% of all human cancers 17 and has been linked with the transcriptional 
activity of numerous nuclear receptors 8,9,13,18. Wild type ARID1A expression is associated 
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with better clinical outcome in ER+ breast cancer patients 19 and importantly ARID1A 
inactivating mutations are enriched in treatment-resistant tumours and metastases (in total 
12% of cases) 20,21. In addition, ARID1A inactivation has been associated as a tumour 
promoting event in ER+ breast cancer 22.
To systematically identify genes involved in treatment response in breast cancer, we 
employed global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 
screening approaches, coupled with three different treatment modalities, which revealed a 
role for the SWI/SNF complex, as critical determinants of treatment response.
Results
A CRISPR screen reveals ARID1A as a gene involved in treatment response
We employed a CRISPR screening approach, which encompassed gRNAs that target a total 
of 18,009 human genes 23. We established Cas9-expressing MCF7 breast cancer cells 
(Supplementary Fig. 1) which were infected and grown for 20 days. All cell line 
experiments were conducted in asynchronous cells grown in estrogen-rich media. Three 
biological cell cultures with independent viral infections with CRISPR vectors were 
performed as described in the Online Methods section. Analysis of the depleted gRNAs at 
different post-infection time-points, revealed known ER interactors including Cyclin D1 
(CCND1), FOXA1 and GATA3 (Fig. 1a and Supplementary Fig. 2, Supplementary Table 1), 
albeit with different essentiality kinetics (Fig. 1a and 1b). In addition, a number of gRNAs 
were enriched representing tumour suppressors or growth inhibitors (Fig. 1c). As expected, 
growth promoting genes required for cellular viability showed greater gRNA depletion with 
longer infection (Fig. 1d). After 9 days of infection, we subsequently treated cells for a total 
of 26 days with the Selective Estrogen Receptor Modulator (SERM) 4-hydroxytamoxifen 
(Tamoxifen) or the Selective Estrogen Receptor Degrader (SERD) Fulvestrant (ICI 182780). 
We also used the tool compound JQ1, which targets Bromodomain and Extraterminal 
Domain (BET)-containing proteins, since Bromodomain containing protein-4 (BRD4) is 
postulated to be a therapeutic target in ER+ breast cancers and BET inhibitors are currently 
being explored in clinical trials 24,25. Three independent infections were performed and the 
data was integrated as described in the methods sections (Complete data in Supplementary 
Table 2). When specifically assessing genes required for treatment response, we found that 
the Fulvestrant and Tamoxifen CRISPR screens looked largely similar (Fig. 1e). Despite the 
distinct mechanisms of growth suppression (Fulvestrant degrades ER, whereas Tamoxifen-
bound ER is recruited to the chromatin as a repressive complex), 63.5% of the genes 
required for Fulvestrant’s antiproliferative effects were also required for Tamoxifen activity 
(Fig. 1e and Supplementary Fig. 2). One of the most significantly enriched gene was AT-
Rich Interaction Domain 1A (ARID1A), a component of the BAF ATP-dependent chromatin 
remodeling complex. It was one of the most essential gene for both Tamoxifen and 
Fulvestrant activity and depletion of ARID1A (i.e. enrichment of gRNAs targeting 
ARID1A) resulted in drug resistance to both compounds. Unexpectedly, ARID1A was the 
highest ranked gene in the JQ1 treated cells (ranked 1 out of 18,009 genes), but in the 
opposite direction, where gRNAs were observed to be depleted in JQ1 treated conditions 
(Fig. 1f, 1g and Supplementary Fig. 2). Other BAF components, including ARID1B, 
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SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily 
B, Member-1 (SMARCB1/BAF47/SNF5) and Synovial Sarcoma Translocation, 
Chromosome 18 (SS18) showed the same pattern (Fig. 1f, 1g and Extended Data 1), 
suggesting that the BAF complex is required for ER targeted drugs to work, but when lost, 
sensitises cells to BET inhibitors. The dependence on ARID1A for growth arrest mediated 
by ER-targeted agents was validated in MCF7 and ZR-75-1 cells using ARID1A siRNA 
(Extended Data Fig. 1, Source Data Fig. 1 and Supplementary Fig. 3).
Genomic characterisation of ARID1A function
We subsequently assessed the potential genomic interplay between ARID1A and ER. We 
performed three independent biological replicates of ChIP-seq for ARID1A in MCF7 and 
ZR-75-1 cells and peaks were called using MACS version 2 26, resulting in 21,226 ARID1A 
peaks in MCF7 and 56,966 peaks in ZR-75-1. ARID1A binding sites were found to 
commonly co-occur at ER and FOXA1 binding events (Fig. 1h and Extended Data 2) and 
global analysis revealed that more than 78% of all ARID1A binding events were shared with 
ER, FOXA1 or both proteins in MCF7 (Fig. 1i), implying a functional connection between 
ARID1A and the regulatory elements occupied by the ER/FOXA1 complex. Interestingly, 
ARID1A overlapped more with FOXA1 (78% ARID1A binding sites were co-bound by 
FOXA1) than with ER (66%) in ZR-75-1 cells (Extended Data 2). We assessed whether 
ARID1A binding to ER bound enhancers was dependent on ER, by hormone depriving cells, 
treating with vehicle (ethanol) or estrogen for 6hr and conducting ChIP-seq. ARID1A was 
able to bind to ER/FOXA1 binding events prior to ligand induced ER recruitment (Fig. 1j 
and Extended Data 2). These findings suggest that ARID1A is not a classic ER-associated 
co-factor and can bind to regulatory elements independent of active ER, likely in a 
repressive manner.
To validate the CRISPR screen, we specifically deleted ARID1A from MCF7 cells, resulting 
in two separate ARID1A knock-out clones (Clones 11 and 14). ARID1A deletion was 
confirmed by Sanger and amplicon-based next generation sequencing and Western blotting 
(Fig. 2a, Supplementary Fig. 4, Source Data Fig. 2) and potential off-target effects were 
assessed. In vitro growth of these clones and the wild type control (WT clone 219) validated 
the CRISPR screening results, showing that both clones had increased intrinsic proliferation 
and were resistant to Tamoxifen, but showed sensitivity to JQ1 (Fig. 2b and Supplementary 
Fig. 5) and two additional clinically relevant BET inhibitors, OTX015 (from OncoEthix/
Merck) and IBET762 (from GlaxoSmithKline) (Supplementary Fig. 4).
We established xenograft tumours from the wild type or the two ARID1A knock-out clones 
in the presence of estrogen pellets to maintain ER+ tumour growth and subsequently treated 
cells with vehicle or 4-hydroxytamoxifen. Tumour growth at day 25 was increased in the 
two ARID1A knock-out clones in the presence of 4-hydroxytamoxifen, when compared to 
wild type mice (Supplementary Fig. 5 which includes details of the statistical tests), 
validating that ARID1A is required for antiestrogen efficacy. However, the greatest 
difference in growth rate was in ARID1A wild type versus knock-out contexts in non-treated 
conditions (Fig. 2c and Supplementary Fig. 5) and we postulated that the diminution in 
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Tamoxifen efficacy in ARID1A-null tumours may simply be due to an increased overall 
intrinsic proliferative potential.
ARID1A regulates ER target genes and is part of the ER complex
To explore the mechanistic role of ARID1A in drug response, RNA-seq was conducted 
using four biological cell culture samples of the wild type or ARID1A knock-out lines, 
treated with vehicle, Fulvestrant, 4-hydroxytamoxifen or BETi (JQ1). Gene expression 
analysis of the ARID1A knock-out clones and controls revealed several findings. The 
control lines looked similar, regardless of whether they were parental cells or wild type 
clonal lines (Supplementary Fig. 8). Whilst Fulvestrant and Tamoxifen showed similar gene 
repression patterns, JQ1 treatment resulted in a substantially different gene expression 
profile (Fig. 2d and Supplementary Fig. 8). In the ARID1A knock-out clones, JQ1 treatment 
showed a more consistent expression pattern when compared to the wild type cells, whereas 
the majority of genes repressed by Fulvestrant/Tamoxifen, were up-regulated or not changed 
in the ARID1A knock-out cells (Fig. 2d and Supplementary Fig. 6). In total, 86% of the 
Fulvestrant and 85% of the Tamoxifen-repressed genes were no longer significantly 
repressed in the ARID1A knock-out cells and a cluster of them (highlighted in Fig. 2d) are 
significantly downregulated by JQ1 treatment, to the same degree as in wild type cells. 
ARID1A deletion therefore, resulted in induction of the Fulvestrant/Tamoxifen repressed 
genes, even in the absence of an ER antagonist, implying ARID1A-mediated basal 
repression of the ER target genes. We generated a gene signature from the RNA-seq data and 
could show in the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) cohort of ER+ breast cancer patients 27 that the ARID1A repressed genes in 
both vehicle and anti-estrogen conditions (those that were up-regulated in the ARID1A 
knock-out cell lines) were associated with poor clinical outcome when up-regulated in 
patients (Fig. 2e and Supplementary Fig. 6 which includes details of the statistical tests), 
again supporting the notion that ARID1A can repress genes linked with clinical outcome.
To understand the mechanism behind ARID1A regulation of innate proliferation, we used an 
unbiased proteomic approach called RIME (Rapid IP-Mass Spec of endogenous 
interactions) combined with a label-free quantification method 28 to identity interactors of 
ARID1A, BRG1 or ER, from asynchronous MCF-7 cells, using an IgG pulldown as a 
negative control (information is provided in supplemental material) (Supplementary Fig. 7). 
ARID1A and BRG1 purification revealed almost all the known BAF components, as well as 
ER and similarly, the ER RIME contained ARID1A and BRG1 in the complex (Fig. 3a, 
Extended Data 3 and Supplementary Table 3 and 4). The other ATP-ase complexes, P-BAF 
and ncBAF 11, are identified in BRG1 pulldown, but not in the ARID1A pulldown. BRG1 
RIME identified all the BAF, P-BAF and ncBAF components, validating that BRG1 is 
common to these complexes 21. It also showed enrichment of GLTSCR1/GLTSCR1L 
(BICRA/BICRL) subunits. BRG1 RIME revealed BET proteins as interactors (data not 
shown). We extended on these observations by re-analysing our recently published ER 
quantitative multiplexed RIME (qPLEX-RIME) data from five ER+ primary tumour samples 
from different patients 29. We discovered ARID1A and several SWI/SNF components, 
including BRG1, BRM, BAF57, BAF170 and BAF155 as physical interactors of ER, even in 
surgical tumour tissue (Fig. 3b, Extended Data 3). Importantly, we also observed an 
Nagarajan et al. Page 5













interaction between ER and BRD4, a target of the BETi, in the patient tumour material (Fig. 
3b), verifying physical associations between endogenous ER, the SWI/SNF complex and 
BRD4 in vivo. We re-analysed our previous proteomic data 29 to identify proteins that 
interact with Tamoxifen-bound ER 29. ARID1A, BRG1 and a number of additional 
SWI/SNF components were enriched with Tamoxifen-liganded ER complex after treatment 
with 4-hydroxytamoxifen for 6hr (Fig. 3c and Extended Data 3), confirming that the SWI/
SNF-ER complex formation is repressive.
To explore the putative functional connection between SWI/SNF and the ER complex, we 
conducted a series of ChIP-seq experiments to map binding sites for ARID1A and two 
SWI/SNF common proteins, BRG1 and SNF5 (BAF47), in estrogen-rich asynchronous 
MCF7 cells treated with control or 4-hydroxytamoxifen for 6hr. Three independent 
biological replicates were conducted. Binding of all three proteins were increased globally 
following 4-hydroxytamoxifen treatment (Fig. 3d and Supplementary Fig. 11), supporting 
the hypothesis that they were involved in drug responsiveness. Both induced BRG1 and 
SNF5 sites overlapped with induced ARID1A sites, ER and FOXA1 (Fig. 3d and 
Supplementary Fig. 8). Unexpectedly, binding of these proteins were also increased 
following Fulvestrant treatment (Extended Data 4). The Fulvestrant-induced sites overlapped 
with both the Tamoxifen gained sites and estrogen lost sites from Fig. 1j (Extended Data 4), 
implying that these are the consistent hormone-regulated SWI/SNF binding regions. 
Altogether, our findings suggest that the recruitment of these factors, whilst able to associate 
with the ER complex, can bind to chromatin in an ER independent manner, in support of 
data showing basal repression of ER target genes by the BAF complex (Fig. 2d and 2e).
FOXA1 recruits ARID1A to chromatin
As Fulvestrant and Tamoxifen both increased BAF binding to chromatin, we speculated that 
the pioneer factor FOXA1, might modulate ARID1A and BRG1 recruitment to the 
chromatin, as supported by the data showing considerable overlap between ARID1A and 
FOXA1 binding (Fig. 1i and Extended Data 2). MCF7 and ZR-75-1 cells were hormone-
deprived and transfected with FOXA1 or control siRNA and ChIP-seq of ARID1A or BRG1 
was conducted. Both ARID1A and BRG1 binding was substantially reduced following 
FOXA1 silencing at enhancers, in both the cell lines assessed (Fig. 4a-e, Extended Data 5-6 
and Supplementary Fig. 9-10), suggesting a degree of dependence on the pioneer factor 
FOXA1 for SWI/SNF recruitment. Importantly, the FOXA1-dependent ARID1A binding 
sites were the same regions where Tamoxifen induced ARID1A binding to the genome (Fig. 
4f-g). To understand the importance of FOXA1 on ARID1A dependent genes, we identified 
the ER bound cis-regulatory elements close to ARID1A-repressed genes (those up-regulated 
in ARID1A knock-out cells), which we had previously shown to correlate with clinical 
outcome (Fig. 2e). We observed a modest change on ARID1A and BRG1 recruitment on 
these sites with FOXA1 loss (Fig. 4h). These findings show that the key ARID1A binding 
events are mediated by FOXA1 and not ER.
We sought to identify the molecular mechanism that dictated decreased drug responsiveness 
when SWI/SNF components were deleted (Fig. 1f and Extended Data 1). We performed 
Assay for Transposase-Accessible Chromatin (ATAC)-sequencing on MCF7 ARID1A 
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knockout or wild type control cells, to assess if ARID1A was required for maintaining 
chromatin accessibility. Four independent cell culture samples were performed. We observed 
233,862 total accessible regions in the genome, of which 83% (n=194,341) were not altered 
in ARID1A knock-out cells. Only 0.7% of sites showed a gain in accessibility in ARID1A 
knock-out cells and 16.3% of sites (n=38,002) sites had decreased accessibility in ARID1A 
knock-out cells (Extended Data 7). Integrative analyses of the chromatin accessibility and 
gene expression datasets showed that genes which are up-regulated in ARID1A knock-out 
cells are more associated with the ATAC-seq gained sites, implicating ARID1A in basal 
repression of these targets via inhibition of chromatin accessibility (Extended Data 7). 
However, there was no significant difference in accessibility at the regions co-bound by 
ARID1A and ER (data not shown), suggesting that loss of ARID1A is not altering 
chromatin accessibility at the regulatory regions bound by these protein complexes.
As previous work showed that a SWI/SNF subunit BRD9 inhibition results in a switch to P-
BAF activity 18, we hypothesised that loss of ARID1A and BAF activity might result in a 
switch to a P-BAF-driven pathway. We therefore conducted ChIP-seq of ARID2 (a P-BAF-
specific complex component) and BRG1 in wild type or ARID1A knock-out clonal cell lines 
and could show that ARID2 binding was not appreciably changed by Tamoxifen treatment 
and there was substantially less ARID2 binding in both ARID1A knock-out clones, 
regardless of the hormonal treatment conditions (Extended Data 8). This is a possible 
consequence of the decreased overall BRG1 binding in the ARID1A deleted cells (Fig. 5a 
and Extended Data 9). As such, loss of ARID1A does not result in recruitment of ARID2 
and a switch to P-BAF dependency.
ARID1A contributes to HDAC1 recruitment and mediating acetylation
To assess the mechanistic basis for the ARID1A repressive function, we performed 
H3K27Ac ChIP-seq and found that it was not affected in the ARID1A knock-out versus 
wild type cells (Extended Data 9). To identify other possibilities explaining the sustained 
gene expression in the presence of ER targeted drugs, when ARID1A was suppressed, we 
explored our RIME data and found that the histone deacetylase protein HDAC1 was an 
ARID1A interacting protein in non-treated conditions (Fig. 3a). In addition, in our qPLEX-
RIME data, HDAC1 recruitment to the ER complex was enriched following Tamoxifen 
treatment, during active gene repression 29. Furthermore, HDAC1 was one of the most 
statistically enriched ER interactors in ER+ primary tumour samples (Extended Data 3) 
compared to IgG controls. We therefore conducted HDAC1 ChIP-seq and found a 
substantial decrease in HDAC1 recruitment, when ARID1A was specifically knocked-out 
(Fig. 5b and Extended Data 9). Only modest changes in ER binding were observed on 
HDAC1 lost sites (Fig. 5c, Extended Data 9 and Supplementary Fig. 11). We also observed a 
modest decrease in global FOXA1 binding as determined by ChIP-seq (data not shown). 
However, this was explained by a parallel decrease in FOXA1 expression, suggesting that 
ARID1A does not directly modulate FOXA1 recruitment to cis-regulatory elements and 
moderately influences FOXA1 binding by affecting total levels of this pioneer factor. BRG1 
and HDAC1 binding was decreased at the same genomic regions in both the ARID1A 
knock-out clones (Fig. 5d and 5e), suggesting that both HDAC1 and BRG1 binding was 
dependent on ARID1A.
Nagarajan et al. Page 7













Additionally, we performed ER qPLEX-RIME on four ER+ Patient-Derived Xenograft 
(PDX) tumours 30, including two that had ARID1A loss via mutation and two ARID1A wild 
type control models (Extended Data 9 and Supplementary Fig. 12). We found a decrease in 
interactions between ER and HDAC1, BAF170 and BAF155 in the ARID1A mutant PDX 
models (Fig. 5f). As such, BRG1-associated SWI/SNF complex physically associates with 
HDAC1 in an ARID1A-dependent manner and the transcriptional repression elicited by 
HDAC1 requires functional ARID1A.
Given that HDAC proteins can actively remove the acetylation marks that are read by BET 
proteins 31, we speculated that changes in HDAC activity might explain the increased 
sensitivity to BET inhibition in the absence of a functional SWI/SNF complex. The histone 
acetylation marks that are read by BET proteins include Histone 4 lysine residues, including 
H4K5Ac, H4K8Ac and H4K12Ac 31. We assessed for increases in these histone marks in 
our ARID1A knock-out cells as a potential consequence of decreased HDAC1 recruitment. 
A distinct subset of histone H4 acetylated sites were increased under both non-treated and 
Tamoxifen treated conditions in the ARID1A knock-out cells, with the most prominent 
change observed in H4K8Ac (Supplementary Fig. 11). To understand the function of H4Ac 
upon ARID1A dependent genes, we examined the adjacent ER bound cis-regulatory 
elements on ARID1A target genes in ARID1A wild type versus knock-out cells. ARID1A 
was recruited to these enhancers in wild type cells and these sites showed substantial 
upregulation of the histone H4 acetylation, particularly H4K8/12Ac in both the clones (Fig. 
5g and Extended Data 10). Given the decreased HDAC1 recruitment, the increase in 
H4K8/12Ac in ARID1A depleted cells and the increased responsiveness to BETi in 
ARID1A deleted contexts (Fig. 1f and 1g), we hypothesised that depletion of ARID1A 
would result in gained BRD4 binding and activity. BRD4 ChIP-seq in wild type and 
ARID1A knock-out cells, revealed a gain of 6,197 BRD4 binding sites in ARID1A depleted 
cells, confirming a significant increase in BRD4 chromatin binding. Analyses on ER binding 
sites close to ARID1A target genes showed increased BRD4 binding under ARID1A loss in 
both treatment conditions (Fig. 6a and 6c). The same regions showed a gain of histone H4 
acetylation and BRD4 and decreased HDAC1 binding in ARID1A-deleted cells (Fig 6b and 
Supplementary Fig. 13-14). We integrated the gained BRD4 binding that was only observed 
in ARID1A-null cells, with the Fulvestrant/Tamoxifen-repressed genes and found a 
significant enrichment of BRD4 recruitment to the genes typically repressed by both ER 
antagonists (Supplementary Fig. 13). Mechanistically, our findings show that depletion of 
ARID1A results in decreased HDAC1 binding, a gain in histone 4 acetylation and coincident 
BRD4 recruitment at regulatory elements adjacent to genes normally repressed by ER 
targeted drugs in wild type contexts (Supplementary Fig. 14). This culminates in increased 
basal proliferation that occurs in a BET-dependent manner. In support of the intrinsic 
regulation of proliferation by ARID1A, we assessed breast cancer patients with ARID1A 
mutations, when compared to patients with wild type ARID1A 27, revealing a poorer clinical 
outcome in women with ARID1A-mutant tumours (Fig. 6d and Supplementary Fig. 14 with 
details of the statistical test). To explore the link between BET-driven growth in ARID1A 
null contexts and to assess other treatment options for women with ARID1A mutations, we 
established a tumour explant from an ARID1A mutant PDX tumour which has a frameshift 
mutation leading to ARID1A loss 30 (Supplementary Fig. 14). Tumour tissue was cultivated 
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ex vivo and treated with vehicle or two different BETi for 48hr and we could show 
significant antiproliferative effects by assessing Ki67 expression, a surrogate marker for 
proliferation, following treatment (Figs. 6e and 6f), confirming the dependence on BET 
proteins in ARID1A mutant/deleted contexts similar to wild type contexts.
Our study shows that the SWI/SNF complex is recruited to ER cis-regulatory elements prior 
to active ER binding, via the pioneer factor FOXA1. ARID1A exhibits transcriptional 
repression by recruiting HDAC1 and when ARID1A is functionally inactivated, HDAC1 
binding is diminished, resulting in a gain in enhancer-specific acetylation, which is 
subsequently ‘read’ by BET proteins (Fig. 6g and Supplementary Fig. 15).
Discussion
Our unbiased genetic screening approach has revealed a critical role for the SWI/SNF 
complex in estrogen receptor-targeted treatment efficacy. Loss of ARID1A had profound 
effects on the gene expression program and growth phenotype, by affecting the chromatin 
environment. Tumour growth and clinical outcome were influenced by ARID1A status, 
independent of estrogen-bound ER activity, in support of previous work showed that BAF57 
could be recruited to the ER target gene promoter, pS2 (TFF1) in an estrogen independent 
manner 12. In contrast, Glucocorticoid Receptor (GR) was shown to recruit the BAF 
complex to the MMTV chromatin template 8,32, implying that the mode of BAF-chromatin 
occupancy is nuclear receptor-specific. Our findings suggest that while ARID1A and 
SWI/SNF components can be recruited to ER cis-regulatory elements by ER antagonistic 
ligands, in particular Tamoxifen, this complex can associate with these enhancer elements 
independent of nuclear receptor activation. In this study, we identified that the pioneer factor 
FOXA1, which demarcates ER regulatory elements 2,33 and binds chromatin independently 
of hormonal status, is responsible for recruiting the BAF complex to the chromatin. FOXA1 
can directly recruit the histone modifying methyltransferase that deposits the histone 
modification that is the hallmark of enhancer elements 34and previous work has shown that 
FOXA1 can open a compacted chromatin template, independently of other proteins 35,36, 
placing it upstream of all factors that subsequently get recruited to these enhancer elements.
Mutation of ARID1A occurs in ~5% of primary breast cancer, but the frequency increases to 
~12% when looking in the metastatic context 20, implying a selection for tumour cells 
possessing loss-of-function ARID1A mutations 20,21. Our findings suggest that loss of 
ARID1A causes a shift in the H4 acetylation status, a result of decreased HDAC1 binding, 
which consequently results in BRD4 recruitment and BET-dependent growth (Fig. 6g). 
Since ARID1A (and other components of the BAF complex) is commonly mutated in many 
cancer types, a role for this complex in regulating general proliferation status may involve 
co-opting the key cell type-specific cis-regulatory elements. Recent studies highlighted the 
possibility of exploiting a synthetic lethality-based treatment strategy in ARID1A-mutant 
ovarian cancers, using inhibitors of BET proteins 37,38. BET inhibitors are proven to be 
effective in ER-dependent breast cancer cells 25 and our current work implies an increased 
dependency on epigenetic readers that drive cell division when the activity of the BAF 
complex is compromised. Given the frequency of BAF mutations in breast cancer, 
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particularly drug resistant contexts, our findings would suggest exploring the potential of 
epigenetic inhibitors that target the BET proteins.
Online Methods
Preparation of Cas9-expressing clones
MCF7 cells were transduced with Cas9 lentiviral vector pKLV2-EF1aCas9T2ABsd-W with 
8 ug/ml Polybrene in 2% serum containing media without antibiotics. Media was replaced 
after 24 hrs with 10% serum, grown for two more days and selected with 30 µg/ml 
Blasticidin for four days. These cells were single cell sorted using (BD FACSAria II) in one 
96 well plate, seeded with very high suspension and diluted into two 15 cm dishes and 
grown in the presence of Blasticidin. After 10 days of growth, single cell clones were hand-
picked and seeded and grown in two 96 well plates. After the clones were grown well, 48 
clones were selected and assessed for Cas9 cutting efficiency using reporter assay in a 6 well 
plate. Cas9 clones were transduced separately with pKLV2-U6gRNA5(GFPg0)-
PGKBFPGFP-W where the cells can express BFP and GFP (control) after 3 days of 
infection and pKLV2-U6gRNA5(GFPg5)-PGKBFPGFP-W which has a gRNA for GFP. 
Highly efficient clones were selected which shows ~95% BFP+ cells in the infected 
population sorted by BD Influx™ Cell Sorter (Supplementary Fig. 1). The average 
efficiency was calculated from 4 independent experiments. Cas9 cut efficiency is calculated 
as follows:
Cas9 efficiency (%) = 100 – (%. of GFP+BFP+cells/(%. of GFP-BFP+cells + %. of GFP
+BFP+cells)*100) which means 100 – (%. of uncut cells/Total % of transfected cells*100)
1C3 clone was selected from FACS-sorted plate and showed 93.9% Cas9 cut efficiency. This 
had been used for initial essentiality screen. 3G1 clone sorted from highly diluted plate 
showed 94.62% Cas9 cut efficiency which was used for drug resistance screening. Both the 
clones were compared after infection with gRNA library after 9 days for their 
reproducibility.
Genome-wide CRISPR screening
Highly efficient Cas9-expressing cells were infected with the human gRNA pooled library 
version-1 with the vector backbone pKLV2-U6gRNA5(lib)-PGKpuroBFP-W23. Cells were 
seeded two days before in a 15 cm dish to ~30 million cells per replicate. Cells were infected 
with 30% transduction efficiency (Supplementary Fig. 1) so that only one gRNA gets 
integrated into the genome per cell. After 3 days (D3), the 30% transduction efficiency was 
verified by FACS sorting in Influx for BFP+ cells. 60 million cells were collected for next 
generation sequencing and antibiotic selection was performed on the remaining cells with 10 
µg/ml Puromycin for 4 days. BFP+ cells were at least 95% after 4 days of antibiotic 
selection which was verified by FACS sorting in Influx. Consequently, 100 million cells 
were collected on different number of days (Day 7, 9, 12, 15 and 20). Genomic DNA was 
isolated from 20-50 million cells using Qiagen Blood & Cell Culture DNA Maxi Kit along 
with RNase treatment.
a. Drug resistance CRISPR screening
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After 9 days of infection with gRNA library, cells were treated with 100 nM 4-
hydroxy-tamoxifen. Fulvestrant and JQ1 were used at 300 nM and 1 µM, 
respectively, at the start of the assay and gradually reduced to 100 nM and 250 
nM, respectively. All treatments were done for 26 days. DMSO was used as a 
control.
b. Library preparation for CRISPR screens
90 µg of genomic DNA from CRISPR library-infected cells which represents 10 
million MCF7 cells (100X representation of gRNA library) were amplified as 5 
ug per reaction (20 times) using primers with lentiviral and Illumina adapter 
sequences with Q5 Hot Start High-Fidelity 2X Master Mix (New England 
biolabs). Primers were noted in Supplementary Table 6. 15 ng of the whole-
genome plasmid library per reaction was used corresponding to 1.7 × 1010 
molecules of the plasmid DNA. PAGE-purified primers (Sigma) were used: PCR 
was done for 25 cycles as follows: Initial denaturation 98°C, 30sec; denaturation 
98°C, 10sec: annealing 61°C, 15sec; extension 72°C, 20sec; final extension 
72°C, 2min. The PCR reaction was verified using Agarose gel electrophoresis for 
the presence of 250 bp PCR product. 5 µl from each reaction was taken, pooled 
and purified using Qiagen PCR purification kit. Second amplification was 
performed on 100 ng of PCR-purified DNA using Illumina dual indices from 
Takara ThruPLEX DNA-seq 96D Kit R400407 and KAPA HiFi HotStart 
ReadyMix for 8 cycles as follows: initial denaturation 98°C, 30sec; denaturation 
98°C, 10sec; annealing 66°C, 15sec and extension 72°C, 20sec; final extension 
72°C, 5min. Final PCR product was purified using Beckman Coulter Agencourt 
Ampure XP beads with 0.7X ratio. Libraries were checked for size by Agilent 
Bioanalyser 2100 or Tapestation 4000 and quantified by qPCR using KAPA 
library quantification kit with ROX Low qPCR Master Mix or Qubit 3.0 
Flurometer. These were pooled and sequenced using an Illumina HiSeq 4000 
with 50 bp single end reads with 30% llumina PhiX Control spike-in version 3. 
30 million reads per sample to sequence every gRNA from every independently 
infected cell.
c. CRISPR screening analyses
Short reads were depleted from low-quality sequences and aligned to human 
gRNA sequence library (GRC h37) using BLAT v. 34 39. Exact-matching reads 
were counted and treated as a measurement of gRNA abundance. Gene ranking 
was performed using MAGecK (Full data is available in the Supplementary 
Table 1 and 2) and log2 fold changes were calculated using DESeq. Heatmaps 
were generated using median log2 fold changes values from gRNAs specific to a 
gene. Plasmid library was used as the control for essential gene screening and 
DMSO for drug resistance screening. Time series clustering was performed using 
dtwclust R package on genes which showed significant enrichment or depletion. 
For the heat-map, Dynamic Time Warp algorithm from dtw R package was used 
for distance measurement followed by hierarchical clustering.
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RNA quality was checked using RNA Integrity Number (RIN) from Bioanalyser and 500 ng 
of RNA was used to prepare libraries using Illumina TruSeq stranded mRNA (HT) library 
preparation kit. Library size distribution was assessed using the Agilent Tapestation 4200 
system. These were sequenced using HiSeq 4000 50 bp single end sequencing. 1% PhiX 
version 3 viral genome spike-in was introduced during sequencing. Fastaq single-end reads 
from multiple lanes were merged to make a single library per replicate. STAR40, version 
2.5.1a, was used to align reads against hg38 reference genome. The read counting was 
performed using the intrinsic function of STAR. Differential gene expression analysis used 
the DESeq2 workflow. All p-values were corrected for multiplicity by means of the 
Benjamini and Hochberg FDR multiplicity correction.
ATAC-sequencing
Omni ATAC-sequencing was performed according to the established protocol from Corces 
et al 41. NX# TDE1, Tagment DNA enzyme and buffer from Illumina were used for the 
transposition reaction. Nextera dual indices were utilized for multiplexing. Sequencing was 
performed using HiSeq 4000 paired end 150 bp reads.
ChIP-seq and ATAC-seq analyses
Reads were mapped to hg38 genome using bowtie2 2.2.642. Aligned reads with the mapping 
quality less than 5 were filtered out. The read alignments from three cell culture samples 
were combined into single library and peaks were called with MACS2 version 
2.0.10.2013121626 using sequences from MCF7 chromatin extracts as a background input 
control. The peaks yielded with MACS2 q value <= 1e-3 were selected for downstream 
analysis. Genrich (https://github.com/jsh58/Genrich) was used to verify the ATAC-seq peaks 
from MACS2. Meme version 4.9.143 was used to detect known and discover novel binding 
motifs amongst tag-enriched sequences.
Differential binding analysis (DiffBind) was performed as described previously 44. For 
visualizing tag density and signal distribution heatmap the read coverage in a window of +/- 
2.5 or 5 kb region flanking the tag midpoint was generated using the bin size of 1/100 of the 
window length.
Gene signature analysis, KM plots
A set of genes that were evaluated as differentially-expressed in RNA-seq analysis and 
located in +/- 50kbp vicinity to the differentially-occupied sites evaluated in ChIP-seq 
analysis was qualified as a potential Gene Signature.
METABRIC27 gene-expression data was accessed via API available at Genomics Data 
Commons portal (https://gdc.cancer.gov/developers/gdc-application-programming-interface-
api) ported to MATLAB. Kaplan-Meier plots and log-rank tests were respectively used to 
display the survival probabilities per group as a function of time and to test if the hazard 
functions of the groups of interest are different. Groups of clinical cases (n>=20) of BC ER+ 
cohorts were stratified by expression of group of genes established at a threshold 
corresponding to most significant difference in survival.
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a. RIME on cell lines
Cells were double cross-linked with 2 mM DSG and 1% Formaldehyde as 
described in ChIP-sequencing in the Supplementary Note. The protocol was 
followed as in ChIP-seq with following modifications: beads were washed 10 
times with RIPA and twice with 100mM ice-cold ammonium hydrogen 
carbonate. Antibodies used: ARID1A (HPA005456), BRG1 (ab215998), ERα 
(ab3575 and Merck Millipore 06-935 antibody mix) and negative control IgG 
(ab171870).
b. qPLEX-RIME on patient-derived xenografts
Frozen clinical tissues were cryosectioned at 30 micron sections and ~90 
sections were double crosslinked with 2mM DSG for 25 mins and 1% 
formaldehyde in the same solution of DSG for 20 mins. Crosslinking was 
quenched with 0.25M Glycine. The pull down was performed with the ER 
antibody mix as mentioned in ChIP-seq and qPLEX-RIME sections.
c. Proteomic sample preparation, LC-MS analysis and Data processing
For sample preparation, trypsin at final concentration 15ng/ul (Pierce) was added 
to the beads followed by overnight incubation at 37°C. A second digestion step 
was performed the next day for 4h and peptides were cleaned with the Ultra-
Micro C18 Spin Columns (Harvard Apparatus) according to manufacturer’s 
instructions. For the qPLEX-RIME experiment, samples were dried and labelled 
with the TMT-10plex reagents (Thermo Fisher) followed by fractionation using 
Reversed-Phase spin columns at high pH (Pierce #84868). For the qPLEX-
RIME, peptide fractions were analysed on a Dionex Ultimate 3000 UHPLC 
system coupled with the nano-ESI Fusion Lumos (Thermo Scientific) mass 
spectrometer.. The full MS scans were performed in the Orbitrap in the range of 
380-1500 m/z at 120K resolution. The MS2 scans were performed in the ion trap 
with CID collision energy 35%. Peptides were isolated in the quadrupole with 
isolation window 0.7Th. The top 10 most intense fragments were selected for 
Synchronous Precursor Selection (SPS) HCD-MS3 analysis with MS2 isolation 
window 2.0Th. The HCD collision energy was set at 65% and the detection was 
performed with Orbitrap resolution 50K. For RIME experiments, peptides were 
analysed on a Dionex Ultimate 3000 UHPLC system coupled with the Q-
Exactive HF (Thermo Scientific) or the Q-Exactive mass spectrometers. The full 
MS scans were acquired in the Orbitrap within the range of 400-1600m/z at 60K 
or 70K resolution respectively. For MS2, the top 10 most intense precursor ions 
were selected with a 2.0Th window followed by HCD fragmentation with 
collision energy 28%. The collected CID and HCD tandem mass spectra were 
processed with the SequestHT search engine in Proteome Discoverer 2.1 and 
Proteome Discoverer 2.2 respectively. The SequestHT included the following 
parameters: Precursor Mass Tolerance 20ppm, Fragment Mass Tolerance 0.5Da 
for CID and 0.02Da for HCD, Dynamic Modifications were Oxidation of M 
(+15.995Da), Deamidation of N/Q (+0.984Da) and Static Modifications were 
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TMT6plex at any N-Terminus/K (+229.163Da) for the qPLEX-RIME 
experiment only. The consensus workflow included calculation of TMT signal-
to-noise and the confidence level for peptide identifications was estimated with 
the Percolator node with decoy database search. The peptide intensities for the 
qPLEX-RIME experiment were normalized and aggregated (by summing) to 
protein intensities. The differential protein expression was performed using 
limma45 implemented in the qPLEXanalyzer tool (10.18129/
B9.bioc.qPLEXanalyzer). The Minora Feature Detector node implemented on 
Proteome Discoverer 2.2 was used for label-free quantification at Maximum ΔRT 
of Isotope Pattern Multiplets 0.2 min and minimum number of isotopes two 
peaks. The consensus workflow included Feature Mapper and Precursor Ions 
Quantifier for Precursor Abundance quantification based on intensity. Complete 
data is available in Supplementary Table 3 and 4.
Sample size calculation for in vivo MCF7 xenografts
The sample size of the study was defined so that, based on effect sizes defined on prior data 
and on nuisance parameters deduced from data of Mohammed et al 46, a global power of 0.8 
would be achieve when testing a chosen set of differences in means of tumor volumes at the 
global 5% level for different time points by means of Welsh’s tests.
In vivo xenografts
All mouse experiments were carried out in Biological Resource Unit at CRUK Cambridge 
Institute. The experiments were in accordance with the UK Animals (Scientific Procedures) 
Act 1986, with approval from the CRUK Cambridge Institute Animal Ethical Review and 
Welfare Body. Age matched (8 weeks) NOD/SCID/IL2Rg−/− (NSG) female mice were 
purchased from Charles River. The animals were verified to be pathogen free and in 
excellent health. Subcutaneous xenografts of MCF-7 cells/ARID1A clones were conceived 
by implanting cells 105 in 50% growth media and 50% matrigel (BD Biosciences), in the 
right flank of 8 weeks old female NSG mice. The mice were also implanted subcutaneously 
with 90 day-slow release 17b-oestradiol (0.72 mg per pellet) hormone pellets (Innovative 
Research of America) into the left flank. After 4 weeks for the efficacy cohort, the tumors 
were randomized and enrolled to the study when the average tumor volume was 100-150 
mm3 size. 8.8 mg/ml of Tamoxifen (Tocris Bioscience, 6342) was made in sterile filtered 
corn oil (Sigma, C8267). The mice were dosed at 20mg/kg, I.P, 6 days a week with 
Tamoxifen. Tumor sizes were monitored twice a week with Vernier caliper measurement.
As tumor volumes show linear growths on the cubic root scale, we used linear mixed models 
to compare the average tumor growth of the different groups as a function of time from 
enrolment on that scale. Linear mixed models allow to take both the within-mouse and time-
dependence into account by means of random effects and auto-regressive parameters 
respectively. We considered here a random intercept and slope model with time since 
enrolment, groups and an interaction between time since enrolment and groups as fixed 
effects, and an autocorrelation structure of order 1 for the error term. Model checks 
suggested a good fit of the model to the data. Sensitivity analyses considering alternative 
modelling (like models including quadratic terms, other kind of time-dependence or other 
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transformations of the tumor volumes) lead to similar conclusions. We used the program R 
(version 3.5.1) and the package nlme (version 3.1-137) to fit linear mixed models. Mean 
values drop for the clones especially at day 18 and 25 as the tumor volume exceeded the 
1500 mm3 limit and were removed from the mice.
Test statistics were shown in Supplementary Fig. S5. In the table S5C, fixed effect estimates 
of the random intercept and slope model used to fit the growth curves in Figure 2C. The 
model intercept corresponds to the tumour size of the MCF7 WT group at day of enrolment 
on the cubic root scale. The coefficient related to the variable Days correspond to the daily 
increase in tumour size for the reference group (MCF7) on the cubic root scale. The two last 
parameters correspond to shift in daily growth of the KO 11 and KO 14 groups compared to 
MCF7.
Explant culture
The ARID1A mutant Patient-Derived Xenograft AB555B was grown in dental sponges as 
previously described 47,48. Spongostan gelatine dental sponges were pre-soaked in explant 
culture media with or without inhibitors (250 nM JQ1 and 1 µM IBET762) and warmed in a 
37°C incubator. One sponge per well was placed in a sterile 24-well tissue culture plate, 
along with 500 µl explant culture media RPMI 1640 (phenol red-free, L-glutamine-free) 
(Gibco, 32404-014) with 10% heat inactivated fetal bovine serum (Gibco A3840401), 2mM 
L-glutamine (Sigma G7513), 10 µg/ml Sigma hydrocortisone (Sigma H0888), 10 µg/ml 
human recombinant insulin (Sigma I9278)), 100 U penicillin, 100 µg streptomycin, 250 ng 
amphotericin B /ml (from 1x Sigma anti-biotic, anti-mycotic solution; #A5955). PDX 
material was cut into 9-12 smaller pieces and each piece was analysed as a replicate. 
Samples on the sponges were incubated with media with inhibitors for 2 days at 37°C with 
5% CO2. These were collected from sponges and fixed in 10% neutral buffered formalin 
overnight at room temperature. Tissues were processed and embedded in paraffin for 
histological assessment. Slides were scanned on an Aperio AT2 (Leica) at 20X 
magnification (resolution 0.5um per pixel) and analysed using HALO software (Indica labs), 
with the multiplex IHC v2.1.1 module.
Statistical analyses
Two-sided tests were used for all the statistical analyses. Bar graphs were shown with 
average values and the box plots with median values. Standard deviation was used to denote 
the error bars in the bar graphs with average values except the proliferation data from 
Incucyte assays where standard error of the mean was used. For boxplots, centre line shows 
the median values with bounds of box corresponding to the first and third quartiles and the 
upper and lower whiskers extend to the largest or the smallest value no further than 1.5 × 
IQR (inter-quartile range). More details about the boxplots on ChIP-seq data are mentioned 
in Supplementary Table 5.
Generation of Genome Edited ARID1A Knock Out clones
CRISPR guides (sgRNA) were designed against Exon 2 of ARID1A (NM_006015). Oligos 
(Sigma Aldrich) were cloned into pSpCas9(BB)-2A-GFP (PX458, Addgene # 48138) as 
previously described49. Guide cutting efficiency was determined in MCF7 and HEK293T 
Nagarajan et al. Page 15













cells using the T7 assay (New England Biolabs, following manufacturer’s instructions). To 
generate independent, non-sister clonal cell lines, MCF7 cells were transiently transfected 
(Lipofectamine 3000, Thermo Fisher Scientific) with PX458-empty (control), PX458-
sgARID1A_2.1 and PX458-sgARID1A2.2, and single cell cloned in 5X 96 well plates per 
gRNA 96h post-transfection by FACS (BD FACSAria II). gDNA was extracted from each 
clone (Extracta DNA Prep, VWR, cat#95091-025) and Exon 2 of ARID1A was amplified by 
PCR (FastStart HF System (Sigma Aldrich, cat#3553361001), primers were noted in 
Supplementary Table 6 (universal Fluidigm tag in lower case). Amplicons were diluted 
1:150 and re-amplified with Fluidigm barcoding primers (incorporating a unique sample 
barcode and Illumina P5 and P7 adapter sequences), pooled and subjected to sequencing 
(Illumina MiSeq platform). The AmpliconSeq analysis pipeline was used for data processing 
and variant calling. Briefly, reads were aligned against the reference genome (GRCh38) 
using BWA-MEM 50 and variants were called using two methods (VarDict51 and GATK 
HaplotypeCaller (https://doi.org/10.1101/201178)). Consensus variants and their effects on 
CRISPR clones were then calculated. All clones used in this paper were STR genotyped and 
confirmed as free from mycoplasma.
Assessment of off-target CRISPR effects
The top three predicted off targets (ACGGCTCCCTGTCCCCGCAG at 
chr1:205061276-205061299; AGAGGCCCCAGACCCCGCAG at chr7:1547994-1548017; 
CCGGCTCCCAGGCCCCGCAG at chr5:10555551-10555574) defined by Desktop 
Genetics with score 88 out of 10049 were verified for their absence of editing with Sanger 
sequencing by amplifying the regions with primers against 3 loci from the final knock-out 
and empty vector control clones (11, 14, 216, 219, 221). Primers are noted in Supplementary 
Table 6.
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Extended Data Fig. 1. Enrichment of BAF and P-BAF components in the CRISPR screen
a. Scatterplot of CRISPR screening data, showing enrichment of BAF components following 
26 days of different drug treatment, relative to DMSO treated control cells. n= 3 independent 
viral infections. b. Log2 fold changes showing gRNA enrichment/depletion against all BAF, 
P-BAF and ncBAF components in the CRISPR screen. Treatment conditions are compared 
to DMSO control. More proliferative changes represent enriched gRNA after treatment, 
indicating genes that contribute to drug resistance. c, e. Validation of ARID1A perturbation 
effect on proliferation and drug response using ARID1A siRNA on MCF7 (c) and ZR-75-1 
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(e), representative experiments shown from 2 similar independent experiments each cell line. 
p-values calculated by One way ANOVA test. * denote p < 0.05, *** denotes p < 0.001. 
Sample size mentioned in S4. Measure of centre represents mean ± SEM (c) and mean ± SD 
(e). d. Western blot of ARID1A protein levels after siRNA transfection in MCF7 cells. A 
representative image is shown from 3 similar independent experiments. Unprocessed 
Western blot in Source Data Fig. 2.
Extended Data Fig. 2. ARID1A co-binds ER and FOXA1-bound regulatory elements, but is 
depleted with estrogen treatment.
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a-c. Single gene profiles showing the binding of ER, FOXA1 and ARID1A on overlapping 
sites in MCF7 cells. ChIP-seq was performed using three independent biological cell 
cultures. d. Overlap of binding sites for ER, FOXA1 and ARID1A binding sites in ZR-75-1 
cells. e. Boxplots showing the normalized ChIP-seq tag density around 400 bp window 
around the center of ARID1A binding on DiffBind-defined estrogen independent (constant) 
and dependent (reduced with estrogen) sites in MCF7. Both classes show reduced ARID1A 
binding upon estrogen. p-values were calculated by Welch’s t-test, two-sided. Centre line 
shows the median values with bounds of box corresponding to the first and third quartiles 
and the upper and lower whiskers extend to the largest or the smallest value no further than 
1.5 × IQR (inter-quartile range). Statistical test details are mentioned in Supplementary Table 
5e.
Extended Data Fig. 3. Enrichment of SWI/SNF factors with ER and FOXA1 in RIME
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a. ARID1A and BRG1 RIME were conducted on asynchronous MCF7 cells on two 
biological cell cultures. Label free quantification was performed to show the log 2 scaled 
normalized intensities of the BAF, P-BAF, ncBAF and common subunits of SWI/SNF 
complex. Rabbit polyclonal IgG is used as the negative control. b. ER qPLEX-RIME was 
performed on five primary tumours from ER+ breast cancer patients and the ER interactors 
are shown as enrichment over IgG vs -log10 p-value, corrected by Benjamini and Hochberg 
multiplicity correction, two-sided. c, d. Boxplots illustrating the more enrichment of 
HDAC1 (c) and less enrichment of random factors (d) in ERα RIME in five patients 
compared to IgG negative control in human breast tumours. The values are scaled to the 
median of IgG and log2 transformed. e. Boxplots illustrating the enrichment of selected 
known ERα interactors from the RIME experiment in MCF7 cells at a representative 
timepoint (4-hydroxytamoxifen- 24 hrs) comparing to IgG negative control. The values are 
scaled to the median of IgG and log2 transformed. n = 5 independent biological cell cultures. 
For all boxplots, Centre line shows the median values with bounds of box corresponding to 
the first and third quartiles and the upper and lower whiskers extend to the largest or the 
smallest value no further than 1.5 × IQR (inter-quartile range).
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Extended Data Fig. 4. Enrichment of SWI/SNF factors during Tamoxifen and Fulvestrant in 
ChIP-seq experiments
a-d. Asynchronous MCF7 cells were treated with vehicle or Fulvestrant, an ER degrader and 
ChIP-seq was conducted for ARID1A (b), BRG1 (c) or SNF5 (d). Triplicate independent 
cell cultures were conducted. d. Single gene profile showing the induction of SWI/SNF 
complex binding during Fulvestrant treatment. e. Overlap of ARID1A lost sites during 
estrogen treatment with gained sites during Tamoxifen and Fulvestrant from three 
independent biological cell cultures. f. Overlap of ARID1A gained sites during Tamoxifen 
treatment with Fulvestrant and Tamoxifen downregulated genes.
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Extended Data Fig. 5. FOXA1 promotes the binding of ARID1A and BRG1.
Hormone-deprived ZR-75-1 cells were transfected with control or FOXA1 siRNA and ChIP-
seq was conducted for ARID1A (a) and BRG1 (b). n = 3 independent biological cell 
cultures. MA plots are shown with the average intensity of binding vs log2 fold change with 
FOXA1 siRNA relative to control siRNA. c. Scatterplot showing the association of the loss 
of ARID1A and BRG1 binding upon FOXA1 knockdown. PCC – Pearson Correlation 
coefficient, two-sided. d. Heatmaps shown on ARID1A and BRG1 FOXA1 independent 
(common) and dependent (lost sites with FOXA1 knockdown) sites in ZR-75-1 cells. e. 
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Boxplots showing the normalized ChIP-seq tag density around 400 bp window of ARID1A 
and BRG1 on FOXA1 independent (constant, n=70,429 sites) and dependent (lost sites with 
siFOXA1, n=17,357 sites) sites in ZR-75-1. p-value calculated by Welch’s test, two-sided. n 
= 3 independent biological cell culture samples. Centre line shows the median values with 
bounds of box corresponding to the first and third quartiles and the upper and lower 
whiskers extend to the largest or the smallest value no further than 1.5 × IQR (inter-quartile 
range). Statistical test details are mentioned in Supplementary Table 5f.
Extended Data Fig. 6. FOXA1 promotes the binding of ARID1A and BRG1.
Hormone-deprived MCF7 and ZR-75-1 cells were transfected with control or FOXA1 
siRNA and ChIP-seq was conducted for ARID1A and BRG1. n = 3 independent biological 
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cell cultures. (a-b) Single gene profiles of CCND1 (a) and CDH1 (b) showing the effect on 
SWI/SNF complex binding with FOXA1 knockdown on MCF7 and ZR-75-1 cells. ER and 
FOXA1 binding overlap is shown. (c-d) ChIP-qPCR analyses on specific sites (CCND1 and 
CDH1 ER binding sites) showing ARID1A and BRG1 binding with FOXA1 knockdown in 
hormone-deprived MCF7 and ZR-75-1 cells (c) or ARID1A binding following Tamoxifen 
treatment in asynchronous MCF7 cells (d). n = 3 independent biological cell cultures. * 
denotes p ≤ 0.05, ** denotes p ≤ 0.01, *** denotes p ≤ 0.001. Precise p-values are 
mentioned in Fig. S10. Mean is measured as centre shown with standard deviation. Details 
of the statistical tests are mentioned in Fig. S10.
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Extended Data Fig. 7. ATAC-seq analyses shows a negligible regulation of ARID1A on 
transcription-associated chromatin opening.
a. Heatmap showing ATAC-seq analysis in ARID1A KO clones 11 and 14 following 
Tamoxifen treatment. Common, gained and lost sites defined by DiffBind analysis. n = 4 
independent biological cell cultures. FDR ≤ 0.05 corrected by Benjamini-Hochberg 
multiplicity correction, two-sided. b. Association of ARID1A KO upregulated and 
downregulated genes with ATAC-seq gained and lost sites.
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Extended Data Fig. 8. ARID1A perturbation regulates ARID2 binding.
a. ARID2 ChIP-seq was conducted in wild type cells or the two ARID1A knock-out clonal 
cell lines and heatmaps are shown on ARID2 binding sites after Tamoxifen treatment. Also 
included was ARID1A ChIP-seq from wild type cells treated with vehicle or Tamoxifen. 
ARID2 binding overlapped with ARID1A binding and was dependent on ARID1A. n = 3 
independent biological cell cultures. b. Signal intensity plot showing changes in ARID2 
binding in wild type control cells or ARID1A knock-out cells at ARID2 binding sites. n = 3 
independent biological cell cultures.
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Extended Data Fig. 9. ARID1A promotes BRG1 and HDAC1 binding without affecting ER and 
H3K27ac occupancy
a, b. BRG1, H3K27Ac, HDAC1 and ER (b) ChIP-seq were conducted in asynchronous wild 
type cells treated with vehicle or tamoxifen or in the two ARID1A knock-out clones (Clones 
11 and 14) following tamoxifen treatment. The binding is shown on regions where HDAC1 
is lost in ARID1A knockout cells relative to wild type cells. n = 3 independent biological 
cell cultures. c, d. Scatterplot showing the correlation of ER (c) or H3K27Ac (d) and 
HDAC1 binding in ARID1A knockout clone 11 versus wild type cells. n = 3 independent 
biological cell cultures. PCC – Pearson Correlation coefficient. p-values were calculated by 
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Pearson correlation test, two-sided. e. Principal Component Analysis (PCA) of normalised 
peptide intensities of PDX tumours after ER qPLEX-RIME. n= 2 PDX each group. f. Details 
of ARID1A mutations observed within ER+ PDX tumours used in ER qPLEX-RIME.
Extended Data Fig. 10. ARID1A regulates histone H4 acetylation.
Upregulation of histone H4 acetylation in ARID1A knock-out clone 11 and 14 in Vehicle (a) 
or Tamoxifen (b) treated cells comparing to wild type cells. Heatmap representing the 
changes in histone H4Ac marks upon ARID1A knockout with Vehicle or Tamoxifen 
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treatment on ER binding sites close to ARID1A repressed genes. n =3. (c) Empirical 
cumulative probability distribution plots of H4K8Ac and H4K12Ac ChIP-seq signals 
showing upregulation in intensity (y-axis) with ARID1A knockouts clones 11 and 14. Plots 
were made on ER sites close to ARID1A repressed genes (n=686 sites) with more than 75% 
contribution to the variance in intensity. Window – 2 kb around the center of binding.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. CRISPR screens reveal ARID1A and BAF components as essential genes for treatment 
response.
Log2 fold of gRNA counts change as a function of time per gene (red lines) and on average 
(black line) based on a sample of n=3 for three categories of genes: the ones showing a rapid 
growth depletion (a), the ones showing a longer-term growth depletion (b) and the ones 
showing increased proliferation (c). For each category, example genes are shown in red and 
ARID1A is shown in blue. d. Heatmap representing log2 fold change of significant genes 
(n=1915) in non-treated conditions (day 3 to day 20 of infection comparing to uninfected 
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gRNA pool). Rows were ordered according to hierarchical clustering. e. Heatmap 
representing log2 fold change of genes after 26 days of treatment with Fulvestrant (Fulv, 
initiated with 300 nM and reduced to 100 nM gradually), 100 nM 4-hydroxytamoxifen 
(Tamox) or BETi (JQ1 – 1µM reduced to 250 nM) comparing to DMSO treatment (DMSO 
control after day 9 of infection). Rows were ordered according to hierarchical clustering. f. 
ARID1A and other BAF components were enriched, but in different directions depending on 
the specific drug treatment. The values show changes in gRNA levels for these genes, using 
a log2 fold change relative to DMSO control. g. Frequency of single gRNAs in log 2 scale 
against BAF complex subunits ARID1A, ARID1B, SMARCB1 and SS18, comparing 4-
hydroxytamoxifen or JQ1 with non-treated conditions. h. Example of ARID1A ChIP-seq 
binding overlap with ER and FOXA1 from MCF7 cells grown in media containing 10% fetal 
bovine serum containing estrogen, from three independent biological ChIP-seq samples per 
group. i. Global overlap between ARID1A, ER and FOXA1 ChIP-seq data from MCF7 cells 
grown in media containing 10% fetal bovine serum containing estrogen (n=3 independent 
biological ChIP-seq samples per group). j. Heatmaps representing ARID1A binding in 
hormone-deprived cells treated with vehicle or 10 nM estrogen (n = 3) on the constant sites 
(n=24,754 sites) defined by DiffBind without any significant change with estrogen treatment 
and the DiffBind-defined significant sites (n=3,023) which show reduced ARID1A binding 
during estrogen treatment. Also shown are the relative ER and FOXA1 binding intensities at 
these regions.
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Fig. 2. ARID1A knock-out clonal cells show loss of response to ER antagonists, but 
responsiveness to BET inhibitors.
a. ARID1A was knocked-out of MCF7 cells using CRISPR deletion. Western blots of 
ARID1A or ER confirm effective gene deletion in clones 11 and 14, with no change in total 
ER levels. This figure shows the data of one representative experiment (Source Data Fig. 2) 
out of the three independent experiments. b. Percentage confluence as a function treatment 
time, in an in-vitro proliferation assay using Incucyte conducted in asynchronous MCF7 
cells treated with vehicle or 1 µM 4-hydroxytamoxifen. This figure shows the data of one 
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representative experiment out of the four independent experiments. Each experiment 
considered n=3 replicated per group. Mean ± Standard error of the mean is shown in the 
graph. c. Xenograft tumour volume of MCF-7 (n=13 animals), ARID1A K.O clone 14 (n=8 
animals), ARID1A K.O clone 11 (n=12 animals) as a function of time since day of 
enrolment. The dots and arrows respectively show the average tumour volume and 
corresponding 95% confidence intervals of mice at risk. Tumour size of animals at different 
time-points were fitted by means of a linear mixed model on the cubic root scale, with time 
and group as fixed effect and random intercepts and slopes for mice (Full details are 
provided in Supplementary Note). The colored curves and shaded areas correspond to the 
fitted growth curves for each group and 95% confidence intervals, and the p-values to the 
mixed model difference in growth rate tests. Test statistics in Fig. S5d. p-values were 
calculated by two-sided Wald test. d. RNA-seq was conducted on the ARID1A knockout 
cells treated with Vehicle, 10 nM Fulvestrant, 100 nM 4-hydroxytamoxifen or 250 µM JQ1 
(n=4 independent biological samples). As controls, both parental MCF7 cells and three wild 
type clonal lines were included. The plot shows fold change of Fulvestrant-regulated genes 
(n=1094) (ordered by means of a hierarchical clustering) in wild type cells. Highlighted 
gene cluster (with a star) shows the maintained downregulated effect of JQ1 regardless of 
ARID1A status, but upregulation with Vehicle and 4-hydroxytamoxifen upon ARID1A loss. 
e. Survival rate as a function of time-to-event for 2 groups of ER+ cancer patients: patients 
showing up- (red) (n=104 for Vehicle and 72 for 4-hydroxytamoxifen) and down- (blue) 
(n=101 for Vehicle and 61 for 4-hydroxytamoxifen) regulation according to a gene signature 
defined by ARID1A targeted genes shown to be repressed by vehicle or 4-
hydroxytamoxifen. p-values correspond to log-rank tests (two-sided) (estimated test 
statistics available in Supplementary Fig. 6) respectively comparing the survival distribution 
of patients with up and down - regulated genes. Total METABRIC cases: 1181.
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Fig. 3. The SWI/SNF complex interacts with ER and is recruited to chromatin following drug 
treatment.
a. ER, ARID1A or BRG1 RIME was conducted in asynchronous MCF7 cells. IgG was used 
as a negative control. ER, FOXA1 and HDAC1 were identified as interactors in the ARID1A 
and BRG1 pull downs and vice versa. Boxplots shows the enrichment of selected known 
interactors in the pulldown samples compared to IgG controls. Pull downs were performed 
in two biological cell culture samples and label free quantification was performed using 
Minora algorithm. The log2 intensities are normalised so that the median of IgGs is zero. 
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Centre line shows the median. n=2 independent biological cell culture samples. b. Five ER+ 
PR+ primary tumour samples were split for ER or IgG pull downs and the enrichment of 
known co-factors in the ER compare to IgGs such as HDAC1 and BAF components are 
shown. Boxplots shows the enrichment of selected known ERα interactors in the ERα 
RIME samples compared to IgG controls in human breast cancer tissues. The log2 values 
are normalised so that the median of IgGs is zero. Centre line shows the median. c. ER 
qPLEX-RIME was conducted in asynchronous MCF7 cells treated with 100 nM 4-
hydroxytamoxifen in a 4-point time course (n = 6 independent biological samples per 
group). Specific BAF proteins are highlighted and the enrichment of the BAF components in 
the ER complex upon 4-hydroxytamoxifen treatment is shown. Centre line shows the 
median. d. ChIP-seq of ARID1A, BRG1 or SNF5 (SMARCB1/BAF47) in asynchronous 
MCF7 cells treated with vehicle (ethanol) or 100 nM 4-hydroxytamoxifen (n = 3 
independent biological ChIP-seq samples). The heatmaps represent the 39,214 ARID1A 
binding events observed after 4-hydroxytamoxifen treatment. Also included are H3K27Ac, 
ER and FOXA1 binding signal intensity at these regions.
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Fig. 4. FOXA1 promotes binding of ARID1A and BRG1 to a subset of potential enhancer 
elements.
a, b. Hormone-deprived MCF7 cells were transfected with control or FOXA1 siRNA and 
ChIP-seq was conducted for ARID1A (a) or BRG1 (b). n = 3 independent biological ChIP-
seq samples. MA plots are shown with the average intensity of binding vs log2 fold change 
with FOXA1 siRNA comparing to control siRNA. c, d. Heatmaps (c) and boxplots (d) 
shown on ARID1A-BRG1 constant (n= 65563 sites) and ARID1A-BRG1 lost sites (n= 9355 
sites) defined by DiffBind following FOXA1 silencing in MCF7 cells. ER and FOXA1 
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overlap are also shown on (c) these sites. n = 3 independent biological cell culture samples. 
p-values (d) were calculated by Welch’s t-test, two-sided. For boxplot, centre line shows the 
median values with bounds of box corresponding to the first and third quartiles and the 
upper and lower whiskers extend to the largest or the smallest value no further than 1.5 × 
IQR (inter-quartile range). More statistical details are mentioned in Supplementary Table 5a. 
e. Scatterplot showing the association of decreased ARID1A and BRG1 binding following 
FOXA1 silencing. PCC – Pearson Correlation coefficient. p-values were calculated by 
Pearson Correlation test, two-sided. f-g. Scatterplot showing the association of ARID1A (f) 
and BRG1 (g) binding following FOXA1 silencing at tamoxifen-induced ARID1A (f) and 
BRG1 (g) binding sites from Fig. 3d. PCC – Pearson Correlation coefficient. p-values were 
calculated by Pearson Correlation test, two-sided. h. Boxplots illustrating the effect of 
siFOXA1 on ARID1A and BRG1 binding on the ER binding sites (n=2,746 sites) close to 
ARID1A repressed genes in Vehicle conditions. p-values were calculated by Welch’s t-test, 
two-sided. Window – 400 bp around center of the factor binding. Centre line shows the 
median values with bounds of box corresponding to the first and third quartiles and the 
upper and lower whiskers extend to the largest or the smallest value no further than 1.5 × 
IQR (inter-quartile range). More statistical details are mentioned in Supplementary Table 5b.
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Fig. 5. Loss of ARID1A results in decreased BRG1 and HDAC1 recruitment and increased 
histone H4 acetylation.
a, b, c. Quantitative signal from BRG1 (a), HDAC1 (b) and ER (c) ChIP-seq within 
ARID1A knock-out cells (n=3 independent biological cell culture samples per group). ChIP-
seq was conducted in the wild type cells or the two ARID1A knock-out clones, showing 
decreased binding of the factors in the absence of ARID1A. Average plots were shown on 
HDAC1 lost sites in the ARID1A knock-out cells. d, e. Scatterplots showing the association 
of decreased BRG1 and HDAC1 binding in ARID1A knockout clone 11 (d) and clone 14 (e) 
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following 100 nM 4-hydroxytamoxifen treatment. n = 3 independent biological cell culture 
samples. PCC – Pearson Correlation coefficient. P-values were calculated by Pearson 
Correlation test, two-sided. f. ER qPLEX-RIME was conducted in four ER+ PDX tumours, 
two of which had loss of ARID1A via mutation (MT1/2) and two were wild type (WT1/2) 
for ARID1A. Heatmaps reveals decreased BAF and HDAC1 interactions with ER in 
ARID1A mutant tumours compare to the wild type tumours. g. We specifically identified 
ARID1A repressed genes in proximity to the ER-bound regulatory elements (n=686 sites) 
that display, according to PCA, more than 75% contribution to the variance in intensity of 
histone H4 acetylation. The data is shown as boxplots. ARID1A dependent genes acquired 
gained H4 acetylation, especially H4K8Ac and H4K12Ac at adjacent enhancers, coincident 
with increased gene expression. P-values were calculated by Welch’s t-test, two-sided. 
Window – 2 kb around center of the binding event. More statistical details are provided in 
Supplementary Table 5c.
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Fig. 6. Loss of ARID1A results in increased BRD4 recruitment and a gain in intrinsic 
proliferation.
a- c. BRD4 ChIP-seq was conducted in wild type or ARID1A knock-out cells (n=3 
independent ChIP-sew samples per group). a. Boxplots were shown on ER bound regions 
close to ARID1A repressed genes (n=686) that display, according to PCA, more than 75% 
contribution to the variance in intensity of H4 acetylation. p-values were calculated by 
Welch’s t-test, two-sided. Window – 400 bp around center of the factor binding. For boxplot, 
centre line shows the median values with bounds of box corresponding to the first and third 
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quartiles and the upper and lower whiskers extend to the largest or the smallest value no 
further than 1.5 × IQR (inter-quartile range). More statistical details are mentioned in 
Supplementary Table 5d. b. Scatterplot showing the association of BRD4 and HDAC1 
binding in the ARID1A knockout clone 11 cells. n = 3 independent biological cell culture 
samples. PCC – Pearson Correlation coefficient. P-values were calculated by Pearson 
Correlation test, two-sided. c. Heatmap shows the gained BRD4 occupancy and decreased 
HDAC1 binding on the ER-bound regulatory elements (n=2,746 sites) adjacent to ARID1A 
target genes. d. Overall patient survival was assessed based on ARID1A mutational status in 
a cohort of 1,824 breast cancer patients. p-value was calculated by log rank survival test, 
two-sided (estimated test statistics available in Supplementary Fig. 14). e. Ki67 IHC protein 
levels stained on an ARID1A mutant PDX cultivated ex vivo and treated with DMSO 
vehicle (n=10 explant chunks), 250 nM JQ1 (n=9 explant chunks) or 1µM IBET762 (n =10 
explant chunks) for 48hr in a single experiment. Median values are shown with p-values 
calculated using Wilcoxon test, two-sided (Wilcoxon test Statistic W= 17 for both 
comparisons). f. Representative images of Ki67 IHC in BETi ex vivo tumour tissue, with 
each image representing a region of 100 μm in length. The explant chunks were treated with 
DMSO vehicle (n=10), 250 nM JQ1 (n=9) or 1µM IBET762 (n =10). g. Model of FOXA1-
ARID1A-HDAC1-BRD4 axis in ARID1A wild type and mutant contexts.
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